**Supplementary data**

**Structure Based Virtual Screening Studies to Identify Novel Potential Compounds for GPR142 and Their Relative Dynamic Analysis for Study of Type 2 Diabetes**

Aman Chandra Kaushik1, 2, Sanjay Kumar3, \*Dong Quing Wei1 and \*Shakti Sahi2

1State Key Laboratory of Microbial Metabolism and School of life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China

2School of Biotechnology, Gautam Buddha University, Greater Noida, U.P, India, 201312

3Molecular Structural Biology Division, CSIR-Central Drug Research Institute Lucknow, India

\*Corresponding authors

**Table S1-** Experimental compounds obtained from literature [1-2], where table indicate EC50 value of chemical structure and structure

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Compounds’ | Structure | Molecular Formula | IUPAC Name | Experimental Activity (EC50) |
| 01 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-001.png | C19H18N4O2 | (2S)-2-amino-N-[2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenylpropanamide | 4.8 |
| 02 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-002.png | C19H18N4O2 | (2R)-2-amino-N-[2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenylpropanamide | 13 |
| 03 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-003.png | C18H16N4O2 | (2S)-2-amino-N-[2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-2-phenylacetamide | >33 |
| 04 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-004.png | C19H24N4O2 | (2S)-2-amino-3-cyclohexyl-N-[2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]propanamide | >33 |
| 05 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-005.png | C12H12N4O2 | 2-amino-N-[2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]acetamide | >33 |
| 06 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-006.png | C19H17ClN4O2 | (2R)-2-amino-3-(2-chlorophenyl)-N-[2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]propanamide | >33 |
| 07 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-007.png | C19H17ClN4O2 | (2R)-2-amino-3-(3-chlorophenyl)-N-[2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]propanamide | >33 |
| 08 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-008.png | C19H17ClN4O2 | (2R)-2-amino-3-(4-chlorophenyl)-N-[2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]propanamide | 3.8 |
| 09 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-009.png | C19H17FN4O2 | (2R)-2-amino-3-(4-fluorophenyl)-N-[2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]propanamide | 4.2 |
| 10 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-010.png | C20H17N5O2 | (2R)-2-amino-3-(4-cyanophenyl)-N-[2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]propanamide | 4.6 |
| 11 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-011.png | C20H20N4O2 | (2R)-2-amino-3-(4-methylphenyl)-N-[2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]propanamide | 6.6 |
| 12 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-012.png | C20H20N4O2 | (2R)-2-amino-3-(4-methylphenyl)-N-[2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]propanamide | 25 |
| 13 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-013.png | C19H17N3O2 | N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenylpropanamide | >33 |
| 14 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-014.png | C21H20N4O3 | (2S)-2-acetamido-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenylpropanamide | >33 |
| 15 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-015.png | C23H24N4O2 | (2S)-2-[(cyclopropylmethyl)amino]-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenylpropanamide | 0.76 |
| 16 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-016.png | C26H24N4O2 | (2S)-2-(benzylamino)-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenylpropanamide | 0.83 |
| 17 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-017.png | C27H26N4O2 | (2S)-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-[(2-phenylethyl)amino]propanamide | 0.78 |
| 18 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-018.png | C23H21N5O2S | (2S)-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.093 |
| 19 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-019.png | C22H20N6OS | (2S)-3-phenyl-N-[4-(pyridin-4-yl)pyrimidin-2-yl]-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.36 |
| 20 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-020.png | C24H22N4OS | (2S)-3-phenyl-N-[3-(pyridin-4-yl)phenyl]-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.088 |
| 21 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-021.png | C25H24N4O2S | (2S)-N-[2-methoxy-5-(pyridin-4-yl)phenyl]-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.089 |
| 22 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-022.png | C25H24N4O2S | (2S)-N-[3-methoxy-5-(pyridin-4-yl)phenyl]-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.053 |
| 23 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-023.png | C25H24N4O2S | (2S)-N-[4-methoxy-3-(pyridin-4-yl)phenyl]-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.24 |
| 24 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-024.png | C25H22N4O3S | 3-[(2S)-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamido]-5-(pyridin-4-yl)benzoic acid | 0.11 |
| 25 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-025.png | C19H19N3OS | (2S)-N,3-diphenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 3.3 |
| 26 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-026.png | C25H24N4OS | (2S)-N-[3-(2-methylpyridin-4-yl)phenyl]-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.052 |
| 27 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-027.png | C24H23N5OS | (2S)-N-[3-(2-aminopyridin-4-yl)phenyl]-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.21 |
| 28 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-028.png | C23H23N5OS | (2S)-N-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 1.9 |
| 29 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-029.png | C22H21N5OS | (2S)-3-phenyl-N-[3-(1H-pyrazol-5-yl)phenyl]-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.067 |
| 30 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-030.png | C23H23N5OS | (2S)-N-[3-(1-methyl-1H-pyrazol-4-yl)phenyl]-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.18 |
| 31 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-031.png | C22H21N5OS | (2S)-3-phenyl-N-[3-(1H-pyrazol-4-yl)phenyl]-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.18 |
| 32 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-032.png | C25H23N3OS | (2S)-3-phenyl-N-(3-phenylphenyl)-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.64 |
| 33 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-033.png | C24H23N5O2S | (2S)-N-[5-(2-methylpyridin-4-yl)-2-oxo-1,2-dihydropyridin-3-yl]-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.067 |
| 34 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-034.png | C21H20N6O2S | (2S)-N-[2-oxo-5-(1H-pyrazol-5-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.20 |
| 35 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-035.png | C22H22N6O2S | (2S)-N-[5-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydropyridin-3-yl]-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.23 |
| 36 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-036.png | C19H18N4O2 | (2S)-2-amino-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenylpropanamide | 4.8 |
| 39 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-037.png | C24H22N4OS | (2S)-3-phenyl-N-[3-(pyridin-4-yl)phenyl]-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.067 |
| 40 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-038.png | C22H19N5O2S | (2S)-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-[(1,3-thiazol-4-yl)amino]propanamide | 0.93 |
| 41 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-039.png | C22H19N5O3 | (2S)-2-[(1,2-oxazol-3-yl)amino]-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenylpropanamide | 2.2 |
| 42 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-040.png | C23H22N6O2 | (2S)-2-[(1H-imidazol-4-ylmethyl)amino]-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenylpropanamide | 0.11 |
| 43 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-041.png | C24H24N6O2 | (2S)-2-{[(1-methyl-1H-pyrazol-3-yl)methyl]amino}-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenylpropanamide | 0.21 |
| 44 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-042.png | C25H23N5O2 | (2S)-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-[(pyridin-2-ylmethyl)amino]propanamide | 0.095 |
| 45 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-043.png | C23H20N6O2 | (2S)-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-[(pyrimidin-2-yl)amino]propanamide | 0.44 |
| 46 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-044.png | C26H25N5O2 | (2S)-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-{[2-(pyridin-2-yl)ethyl]amino}propanamide | 1.32 |
| 48 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-046.png | C24H26N4O3 | (2S)-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-2-[(oxolan-2-ylmethyl)amino]-3-phenylpropanamide | 0.39 |
| 49 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-047.png | C26H30N4O3 | (2S)-2-{[2-(oxan-4-yl)ethyl]amino}-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenylpropanamide | 1.06 |
| 50 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-048.png | C24H25N5O3 | (2S)-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-2-{[(5-oxopyrrolidin-2-yl)methyl]amino}-3-phenylpropanamide | 2.23 |
| 51 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-049.png | C26H25N5O2 | N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-{[(1S)-1-(pyridin-2-yl)ethyl]amino}propanamide | 0.22 |
| 52 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-050.png | C26H25N5O2 | N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-{[(1R)-1-(pyridin-2-yl)ethyl]amino}propanamide | 6.0 |
| 53 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-051.png | C27H27N5O2 | N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-{[1-(pyridin-2-yl)propyl]amino}propanamide | 0.73 |
| 54 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-052.png | C27H27N5O2 | N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-{[2-(pyridin-2-yl)propan-2-yl]amino}propanamide | 9.45 |
| 55 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-053.png | C27H25N5O2 | N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-{[1-(pyridin-2-yl)cyclopropyl]amino}propanamide | 0.054 |
| 56 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-054.png | C26H24N6O2 | N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-{[1-(pyrimidin-2-yl)cyclopropyl]amino}propanamide | 0.099 |
| 57 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-055.png | C26H25N5O2S | 2-{[1-(2-methyl-1,3-thiazol-4-yl)cyclopropyl]amino}-N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenylpropanamide | 0.20 |
| 58 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-056.png | C29H27N5O4 | 2-{2-oxo-3-[(2S)-3-phenyl-2-{[1-(pyridin-2-yl)cyclopropyl]amino}propanamido]-5-(pyridin-4-yl)-1,2-dihydropyridin-1-yl}acetic acid | 0.26 |
| 59 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-057.png | C31H34N6O2 | (2S)-N-{1-[2-(dimethylamino)ethyl]-2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl}-3-phenyl-2-{[1-(pyridin-2-yl)cyclopropyl]amino}propanamide | 0.28 |
| 60 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-058.png | C28H27N5O2 | (2S)-N-[2-methoxy-5-(pyridin-4-yl)pyridin-3-yl]-3-phenyl-2-{[1-(pyridin-2-yl)cyclopropyl]amino}propanamide | 0.35 |
| 61 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-059.png | C20H18N6OS2 | (2S)-3-phenyl-N-[5-(pyridin-4-yl)-1,3,4-thiadiazol-2-yl]-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.086 |
| 62 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-060.png | C21H21N7OS2 | (2S)-N-{5-[2-(methylamino)pyridin-4-yl]-1,3,4-thiadiazol-2-yl}-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.036 |
| 63 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-061.png | C19H19N7OS2 | (2S)-N-[5-(1-methyl-1H-imidazol-5-yl)-1,3,4-thiadiazol-2-yl]-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | 0.18 |
| 64 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-062.png | C18H16N6OS3 | (2S)-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]-N-[5-(1,3-thiazol-5-yl)-1,3,4-thiadiazol-2-yl]propanamide | 0.39 |
| 66 | C:\Users\Aman\Desktop\Drug\Experimental Compounds\Compound-063.png | C25H23N5O2 | N-[2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl]-3-phenyl-2-[(pyridin-2-ylmethyl)amino]propanamide | 0.095 |

**Table S2-** Top 10 compounds are short listed from combined 3D Database of GPR142; where compound21 shown best docking affinity with penta ring structure that help to inhibit the Type 2 diabetes, where ADMET properties was calculated by ALOGPS2.1 program and basic feature were calculate using chemicalize program. Top 10 compounds are short listed from combined 3D Database of GPR142; where compound21 shown best docking affinity with penta ring structure that help to inhibit the Type 2 diabetes.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Compound’s | Compound 2D | Molecular Formula | IUPAC Name | Docking Score (VSW) | Molecular Weight | LogP | LogS |
| Compound21 | C:\Users\Aman\Desktop\Drug\Pharmacophore Compounds\21-001.png | C24H18N5O2S | (6S)-4-oxo-6-{[(4-phenylphenyl)amino]methaniumoyl}-2-[(1,3λ⁴-benzothiazol-2-ium-3a-ylium-3-id-2-yl)imino]-3,4,5,6-tetrahydro-1λ¹-pyrimidine-2,4-bis(ylium)-1-uide | -6.470 | 442.511g/mol | 3.00 | -5.88 |
| Compound22 | C:\Users\Aman\Desktop\Drug\Pharmacophore Compounds\22-001.png | C19H17N6O3S | 5-[(2-{[3-(1,3-benzodiazol-2-yl)-1,2-dihydropyridin-2-ylium-1-id-2-yl]sulfanyl}ethan-1-iumoyl)amino]-6-methyl-2,4-dioxo-1λ¹,3λ¹-pyrimidin-2-ylium-1,3-diuide | -7.060 | 409.442g/mol | -0.38 | -5.20 |
| Compound23 | C:\Users\Aman\Desktop\Drug\Pharmacophore Compounds\23-001.png | C21H17F3N4OS | 2-{[3-(1,3-benzodiazol-2-yl)pyridin-2-yl]sulfanyl}-1-oxo-1-{[2-(trifluoromethyl)phenyl]amino}ethanium | -6.668 | 430.446g/mol | 0.65 | -6.76 |
| Compound24 | C:\Users\Aman\Desktop\Drug\Pharmacophore Compounds\24-001.png | C23H24N5O4S | 1,3-dimethyl-7-[(4-methylphenyl)methyl]-8-({2-[(3-oxidophenyl)amino]-2-oxoethan-2-ium-1-yl}sulfanyl)-2,3,6,7,8,9-hexahydro-1H-purine-2,6,8-tris(ylium)-2,6-bis(olate) | -6.826 | 466.532g/mol | 0.57 | -4.86 |
| Compound25 | C:\Users\Aman\Desktop\Drug\Pharmacophore Compounds\25-001.png | C25H24FN6O2 | 3-{[({1-[(4-fluorophenyl)methyl]-1H-1,2,3,4-tetrazol-5-yl}methyl)(furan-2-ylmethyl)amino]methyl}-6-methyl-2-oxo-1,2-dihydroquinolin-2-ylium | -6.645 | 459.4949g/mol | 2.58 | -4.38 |
| Compound26 | C:\Users\Aman\Desktop\Drug\Pharmacophore Compounds\26-001.png | C23H26N3O4S | (2R,4R)-2-[(1R)-2-(benzylamino)-2-oxo-1-[(2-phenylethan-1-iumoyl)amino]ethan-2-ium-1-yl]-4-[hydroxy(oxido)methyl]-5,5-dimethyl-1,3-thiazolidin-3-ide | -7.339 | 440.535g/mol | 2.34 | -4.90 |
| Compound27 | C:\Users\Aman\Desktop\Drug\Pharmacophore Compounds\Compound7 Substitute-001.png | C26H18N3O | 2-{2-[(naphthalen-1-yl)imino]-2H-chromen-2-ylium-3-yl}-1λ¹,3λ¹-benzodiazole-1,3-diuide | -7.161 | 388.441g/mol | 2.93 | -6.86 |
| Compound28 | C:\Users\Aman\Desktop\Drug\Pharmacophore Compounds\28-001.png | C23H30NO4 | 1-{4-[(2R)-2-oxido-3-(4-oxido-4-phenylpiperidin-1-yl)propoxy]phenyl}-1-oxopropan-1-ium | -6.290 | 384.489g/mol | 2.15 | -5.17 |
| Compound29 | C:\Users\Aman\Desktop\Drug\Pharmacophore Compounds\29-001.png | C25H31N6O2 | 3-({[(1R)-1-(1-benzyl-1H-1,2,3,4-tetrazol-5-yl)propyl](2-oxidoethyl)amino}methyl)-6,7-dimethyl-2-oxo-1,2-dihydroquinolin-2-ylium | -6.742 | 447.552g/mol | 2.18 | -5.30 |
| Compound30 | C:\Users\Aman\Desktop\Drug\Pharmacophore Compounds\30-001.png | C31H27FN6O2 | 3-[(S)-(1-benzyl-1H-1,2,3,4-tetrazol-5-yl)({[(4-fluorophenyl)methyl](furan-2-ylmethyl)azanidyl})methyl]-6-methyl-1λ¹-quinolin-2-ium-8a-ylium-1-uid-2-olate | -6.887 | 534.584g/mol | 4.72 | -4.04 |
| CompoundE1 | C:\Users\Aman\Desktop\T2D_GPR119_Elsevier\PlosOne\Frontiers\Experimental-001.png | C21H21N7OS2 | (2S)-N-{5-[2-(methylamino)pyridin-4-yl]-1,3,4-thiadiazol-2-yl}-3-phenyl-2-[(1,3-thiazol-4-ylmethyl)amino]propanamide | -4.860 | 450.56g/mol | 2.54 | -4.67 |

**Table S3-** Top 20 screened chemical compounds using virtual screening.

|  |  |  |
| --- | --- | --- |
| Compounds | Compound 2D |  |
| 01 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_DrugBank_Investigational_Compound1-001.png** | C18H23N5O21P4 |
| 02 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Ligand_Info_1_Compound1-001.png** | C27H30O16 |
| 03 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Ligand_Info_1_Compound2-001.png** | C28H32O15 |
| 04 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_DrugBank_Approved_Compound1-001.png** | C19H26I3N3O9 |
| 05 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Ligand_Info_1_Compound3-001.png** | C21H26N7O14P2 |
| 06 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Zinc13-001.png** | C41H42O6 |
| 07 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Zinc2-001.png** | C29H30N6O4S1 |
| 08 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Ligand_Info_5_Compound1-001.png** | C30H35N3O2 |
| 09 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Ligand_Info_4_Compound1-001.png** | C20H21N1O8P1 |
| 10 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Ligand_Info_5_Compound3-001.png** | C22H30N4O6 |
| 11 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_PUBCHEM-001.png** | C21H24N2O5P1 |
| 12 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Ligand_Info_5_Compound4-001.png** | C22H19Cl3O5 |
| 13 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Zinc14-001.png** | C12H20N3O7 |
| 14 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Schrodinger_pt_flex-001.png** | C29H28F1N5O4S1 |
| 15 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Zinc9-001.png** | C41H32O11 |
| 16 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Ligand_Info_5_Compound5-001.png** | C20H21N1O8P1 |
| 17 | **C:\Users\Aman\Desktop\Drug\Compound17 Information\Compound17-001.png** | C33H32N4O8 |
| 18 | **F:\PhD Papers\Drug Designing GPR142\Aman_VS_50ns_GPR142\GPR142_Screened_2DLigand\Docked_GPR142_Ligand_Info_5_Compound7-001.png** | C24H34N4O6 |
| 19 | **A:\Communicated Papers\GPR142 Drug Designing Paper\1920complex\Compound19-001.png** | C26H38N2O4 |
| 20 | **A:\Communicated Papers\GPR142 Drug Designing Paper\1920complex\Compound20-001.png** | C23H19NO10 |

**Figure S1:** Interaction fraction analysis of binding pocket residues with A) compound 2 and B) compound 21 during simulation. Residues order number are changed due to rearrangement of simulation system during building of MD system (Water model+ Membrane model+ Ions+ Protein Complexes).

****